Get the Stockscreener App
2.38
0.42%
0.010
After Hours:
2.37
-0.010
-0.42%
Compugen Ltd stock is traded at $2.38, with a volume of 77,724.
It is up +0.42% in the last 24 hours and down -17.07% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
See More
Previous Close:
$2.37
Open:
$2.4
24h Volume:
77,724
Relative Volume:
0.30
Market Cap:
$225.45M
Revenue:
$72.66M
Net Income/Loss:
$34.86M
P/E Ratio:
6.5027
EPS:
0.366
Net Cash Flow:
$-62.91M
1W Performance:
-4.42%
1M Performance:
-17.07%
6M Performance:
+15.53%
1Y Performance:
+72.46%
1-Day Range:
$2.345
$2.42
1-Week Range:
$2.305
$2.495
52-Week Range:
$1.37
$3.235
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.38 | 224.51M | 72.66M | 34.86M | -62.91M | 0.366 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Initiated | Lake Street | Buy |
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Compugen to host virtual event on COM701 ovaria... - Pluang
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026 - Yahoo Finance
Compugen Stock Price Forecast. Should You Buy CGEN? - StockInvest.us
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - Eastern Progress
Compugen Shareholders Approve All Proposals at 2026 Annual Meeting - The Globe and Mail
All 2026 AGM proposals pass at Compugen (CGEN) - Stock Titan
Israel National Biotech Innovation Center Launches With Anat Cohen-Dayag as CEO of INBI Core - citybiz
Compugen to present at H.C. Wainwright Investme... - Pluang
A cancer treatment company will speak live Sept. 14. Compugen’s talk will be webcast. - Stock Titan
New initiative seeks $500m to commercialize Israeli life scienceGlobes - Globes - Israel Business News
Compugen (CGEN) Holds Near $2.62 as Shares Navigate Tight $2.49–$2.75 RangeBullish Pattern Stocks - careplusvn.com
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy - Yahoo Finance
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress
Are Medical Stocks Lagging Compugen (CGEN) This Year? - Yahoo Finance
Compugen (CGEN) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Price Reaction: Shares Finish 1.28% Up on the DayCost Structure Review - dars.gov.et
Compugen (CGEN) Dips 2.49% to $2.35, Pressure Mounts Toward Support at $2.23Price Target - vinanet.vn
Analysts Have Just Cut Their Compugen Ltd. (NASDAQ:CGEN) Revenue Estimates By 14% - simplywall.st
CGEN Q2 2026 Earnings: Loss Narrower Than Expected as EPS Surprises PositivelyMargin Expansion Trends - vinanet.vn
Compugen Ltd. (CGEN) Slides 3.6% as Biotech Stock Approaches Key $2.29 SupportBuy Signal Reports - vinanet.vn
Compugen (NASDAQ:CGEN) Share Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Compugen (CGEN) Slips 1.8% to $2.46 as Shares Hover Near Key SupportSingle Stock ETF - Vinanet
Compugen (CGEN) Gains 4.17% to $2.50 as Immuno-Oncology Stock Shows ResilienceRange Breakout - careplusvn.com
Compugen (CGEN) Q2 2026 Earnings Call Transcript - AOL.com
Compugen (CGEN) Slips 2.9% to $2.34 as Shares Approach Key Support at $2.22RVOL Spike - careplusvn.com
Compugen Ltd. (CGEN) stock price, news, quote and history - Yahoo Finance Singapore
Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Compugen Ltd (CGEN) Stock News Today - TradingKey
Compugen Ltd. (CGEN) Rises 2.17% to $2.35: Biotech Stock Holds Key Support as Resistance at $2.47 LoomsMFI Overbought - vinanet.vn
Compugen: Better Runway Ahead Of MAIA - Seeking Alpha
FY2026 EPS Estimates for Compugen Raised by HC Wainwright - MarketBeat
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ... By GuruFocus - Investing.com Canada
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Compugen stock maintained at Buy by H.C. Wainwright on trial data - Investing.com South Africa
H.C. Wainwright Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Compugen Ltd. (NASDAQ:CGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Compugen (CGEN) Stock Holds Steady As Cash Runway Extends To 2029 - simplywall.st
CGEN Looks 54.6% Undervalued on GF Value™ - GuruFocus
Earnings call transcript: Compugen Q2 2026 revenue misses forecast as cash runway extends - Investing.com Canada
Compugen Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Compugen Q2 Earnings Call Highlights - TradingView
CGEN: Revenue doubled and clinical programs advanced, supporting a strong outlook into 2029 - TradingView
Compugen Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Compugen Ltd Earnings Call Transcript - GuruFocus
Compugen (NASDAQ: CGEN) seeks votes on directors, pay policy and auditor - Stock Titan
COMPUGEN ($CGEN) Releases Q2 2026 Earnings - Quiver Quantitative
Compugen (NASDAQ:CGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Compugen (NASDAQ: CGEN) reports H1 2026 results, cash runway into 2029 - Stock Titan
Compugen Reports Second Quarter 2026 Results - Yahoo Finance
Compugen announces annual shareholder meeting - Bitget
Compugen (CGEN) Edges Higher at $2.35 as Biotech Sentiment SteadiesQuote Data - careplusvn.com
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):